A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Prior treatment

• History of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures.
• Had major surgery, donated, or lost 1 unit of blood within 4 weeks prior to the pre-study visit.

Other illness

• History of a primary DSM-5 axis I psychiatric diagnosis other than schizophrenia or schizoaffective disorder per the allowed DSM-5 criteria.
• History of intellectual disability, borderline personality disorder, anxiety disorder, or organic brain syndrome.
• History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia (TD).
• History of cancer.
• History of frequent syncope, vasovagal episodes, or epileptic seizures.
• Family history of sudden cardiac death.
• Has a positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV).

Lab values

• History or presence of sick sinus syndrome, atrioventricular (AV) block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QTc interval, or conduction abnormalities.
• History of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome).

• Meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria.
• Is in the non-acute phase of their illness.
• Has a history of receiving and tolerating antipsychotics medication within the usual dose range employed for schizophrenia.
• Participants with hypothyroidism, diabetes, high blood pressure, chronic respiratory conditions or other medical conditions could be considered if their condition is stable.